Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: A real-life effectiveness and cost impact evaluation
Asthma has a substantial impact on quality of life and health care resources. The identification of a more cost-effective, yet equally efficacious, treatment could positively influence the economic burden of this disease. Fluticasone propionate/Formoterol (FP/FOR) may be as effective as Fluticasone Salmeterol (FP/SAL). We evaluated non-inferiority of asthma control in terms of the proportion of patients free from exacerbations, and conducted a cost impact analysis.
Source: Respiratory Medicine - Category: Respiratory Medicine Authors: Simon Wan Yau Ming, John Haughney, Iain Small, Stephanie Wolfe, John Hamill, Kevin Gruffydd-Jones, Cathal Daly, Joan B. Soriano, Elizabeth Gardener, Derek Skinner, Martina Stagno d'Alcontres, David B. Price Source Type: research
More News: Advair | Advair Diskus | Asthma | Flonase | Flovent | Health Management | Respiratory Medicine